Several markers, including CD44, ALDH and CD133, have been used successfully to isolate CSCs from breast, prostate, colorectal, glioblastoma, and pancreatic cancers [13]–[17], and CD133 has previously been identified as a putative CSC marker for ATC. This evidence concerns the gene PROM1 and pancreatic neoplasm.